Endocrine Research Updates

For Medical Professionals

People with type 1 diabetes are at increased for Addison's disease, too.
For the first time, predictive clinical signs of Addison's disease have been identified in people with type 1 diabetes, making an earlier diagnosis possible.
Criteria to diagnosis Addison's disease in people with type 1 diabetes has been found, promising earlier detection and better outcomes.
Need to treatment people with type 2 diabetes for reduce heart disease risk too.
An American College of Cardiology expert statement advises clinicians to take a more concerted, consistent effort in achieving cardiovascular risk reduction in patients with both type 2 diabetes and atherosclerosis.
Using tablets (iPads) makes medical data readily available.
When clinicians encourage patients to utilize digital and online health technology and employ these
Patients are likely to present with multiple autoimmune disorders.
The prevalence of polyautoimmunity in people with Graves’ disease, and the rise of Multiple Autoimmune Syndrome in patients with endocrine disorders will require greater diagnostic and management investment.
Common conditions like sleep apnea arise frequently in people with acromegaly.
Sex differences in symptoms and early manifestations recognized by patients before clinicians, and identification and screening for common comorbidities still lacking despite published guidelines.
Experts questions validity of copeptin over water-deprivation testing.
Might blood testing for copeptin offer an easier diagnostic method than the customary water-deprivation in assessing for diabetes insipidus? The researchers recommend copeptin as the new gold standard but longtime experts express caution.
Buyer beware: Nutritional supplements may include toxic substances.
Patients must be warned of possible health consequences from banned, potentially dangerous pharmaceuticals, and other undisclosed ingredients in so-called natural, nutritional supplements.
ADA prioritizes access to affordable ongoing diabetes patient education.
In an ADA/EASD consensus report on type 2 diabetes treatment, involving patients in their care is the best way forward in achieving optimal blood glucose control, better outcomes, and reducing complications.
Testosterone replacement therapy may be beneficial in men with COPD.
Testosterone replacement therapy may be warranted to reduce hospitalizations for chronic obstructive pulmonary disease.
Watiing for diagnosis of osteoporosis may put older women at risk for death.
Post-menopausal women who do not meet the definition of osteoporosis may be candidates for earlier intervention with bisphosphonate therapy.
People with higher risk for diabetes complications need more aggressive therapy.
STOP Diabetes trial results suggest significant benefits in patients deemed at higher risk for type 2 diabetes who receive more aggressive pharmacotherapy, against lifestyle and metformin to reverse diabetes and associated complications.
Adding locaserin may improve reduce heart disease, obesity and diabetes.
Brief news features on recently released FDA approvals and preliminary clinical trials results for the weight loss drug locaserin, a diabetes combination therapy, and inhaled insulin.
New study supports first effective treatment for cardiomyopathy in diabetes.
Researchers say tafamidis may also slow cognitive functional decline; findings were lauded by an independent expert who called cardiovascular benefits ''substantial."
Non-alcoholic fatty liver disease is strongly associated with hypothyroidism.
A closer look at new data supports a strong association between low thyroid function and liver disease with likelihood of non-alcoholic fatty liver disease tied to degree of hypothyroidism.
Late effect growth hormone deficiency is rising in children treated for cancer.
Seeking better overall care, as the prevalence of cancer survivorship grows in the pediatric population, so may the risk for late effect growth hormone deficiency, particularly among those receiving radiation.
Treatment with specialized antibody preserves pancreatic beta cell function.
Early introduction of a specialized antibody agent may preserve β-cell function to sufficiently improve HbA1c in new-onset type 1 diabetes.
A combination of Dapa and a potent omega 3 agent seem to treat NAFLD.
Combination therapy with SGLT2i and a potent omega-3 formula appears to reduce liver fat content; and dapagliflozin alone may be disease-modifying for NAFLD.
Until now, the only treatment for nonalcoholic fatty liver disease is weight loss but combination therapy with an SGLT2i plus omega 3 holds promise.
People with type 2 diabetes have different risk factors for heart disease.
Inflammation and endothelial stress increase the risk for cardiovascular disease, and the severity of atherosclerosis raises the risk further in patients with no prior history of CVD.
New molecular tests deliver clear cytological analysis of thyroid tumors.
A closer look at the validity and efficacy of four molecular tests, including an expert review and assessment of their recommended use in clinical practice.
New research is bringing the prospect of a diabetes ever closer.
The potential for achieving remission in newly diagnosed diabetes appears feasible given recent evidence that changes that induce beta cell function may induce disease remission for type 1 diabetes and reverse type 2 diabetes.